CEFTAZIDIME FOR INJECTION BP 2 G — DIN 02437856
CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE) : 2 G · STERIMAX INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CEFTAZIDIME FOR INJECTION BP?
CEFTAZIDIME FOR INJECTION BP 2 G contains CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE) : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02437856, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-May-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFTAZIDIME FOR INJECTION BP used for?
Treatment of infections: Lower Respiratory Tract, Urinary Tract, Skin Structure, Bacteremia/Septicemia, Bone, Peritonitis, and Meningitis caused by susceptible strains of designated organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ceftazidime cost around the world?
Ceftazidime is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 21 | 24 | SAR███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| South Africa | single exit price | 9 | 12 | ZAR███.██ |
| Morocco | PPV (public price) | 4 | 5 | MAD███.██ |
| Bahrain | retail (max) | 4 | 4 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| United States | acquisition | 1 | 2 | USD███.██ |
62 pack listings across 54 brand entries and 7 price bases, refreshed 05 Sep 2026. Ranges span every Ceftazidime pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ceftazidime in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Ceftazidime, across 23 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| STERIMAX INC | 4 | 3 | CEFTAZIDIME FOR INJECTION BP, CEFTAZIDIME FOR INJECTION, BP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 3 | 3 | CEFTAZIDIME FOR INJECTION, USP | Sourceable in Canada |
| GLAXO CANADA INC | 7 | 0 | CEPTAZ INJ 10GM/VIAL, CEPTAZ INJ 1GM/VIAL, CEPTAZ INJ 2GM/VIAL, FORTAZ INJ 1GM/VIAL, FORTAZ INJ 2GM/VIAL, +2 more | No marketed DIN |
| GLAXOSMITHKLINE INC | 6 | 0 | CEPTAZ INJECTION - PWS IM IV 1G/VIAL, CEPTAZ INJECTION - PWS IV 10GM/VIAL, CEPTAZ INJECTION - PWS IV 2GM/VIAL, FORTAZ | No marketed DIN |
| ELI LILLY CANADA INC | 3 | 0 | TAZIDIME ADD-VANTAGE INJ 1.0GM/VIAL, TAZIDIME ADD-VANTAGE INJ 2GM/VIAL, TAZIDIME INJ 500MG/VIAL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 1 g and 2 g vials (packs of 10); 3 g and 6 g Pharmacy Bulk Vials (single packs). Vials contain ceftazidime pentahydrate and sodium carbonate. |
| Storage | Dry state: Store between 15-30°C and protect from light. Reconstituted solutions: See monograph for specific stability (e.g., 8 hours at room temperature for bulk vials). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Ceftazidime |
|---|---|
| ATC code | J01DD02 |
| AHFS class | 08:12.06.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02437856 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2437856 |
| Brand name | CEFTAZIDIME FOR INJECTION BP |
| Generic / active ingredient | CEFTAZIDIME (CEFTAZIDIME PENTAHYDRATE) : 2 G |
| Market authorization holder | STERIMAX INC |
| Health Canada schedule | Prescription |
| ATC code | J01DD02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DD |
| Current status | MARKETED |
| Status date | 29-May-2015 |
| Original market date | 2015-05-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 0.5 to 6 g daily in divided doses every 8-12 hours. Pediatrics: 25-50 mg/kg q12h (neonates) or 30-50 mg/kg q8h (infants/children). Administer IV or IM. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ceftazidime or the cephalosporin group of antibiotics. History of cephalosporin-associated hemolytic anemia.
Warnings and precautions
Serious hypersensitivity (anaphylactic) and severe cutaneous adverse reactions (SCAR). Hemolytic anemia. Clostridium difficile-associated disease. Neurologic events in renal impairment.
Is Ceftazidime in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by STERIMAX INC, last seen 23 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 23 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFTAZIDIME FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02437848 |
| CEFTAZIDIME FOR INJECTION BP | 6 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02437864 |
| CEFTAZIDIME FOR INJECTION, USP | 6 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 00886963 |
| CEFTAZIDIME FOR INJECTION, USP | 2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 00886955 |
| CEFTAZIDIME FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 00886971 |
| CEFTAZIDIME FOR INJECTION, BP | 3 G | POWDER FOR SOLUTION | STERIMAX INC | DORMANT | 02439522 |
| CEPTAZ INJ 10GM/VIAL | 10 G | POWDER FOR SOLUTION | GLAXO CANADA INC | CANCELLED POST MARKET | 01968092 |
| CEPTAZ INJ 1GM/VIAL | 1 G | POWDER FOR SOLUTION | GLAXO CANADA INC | CANCELLED POST MARKET | 01974408 |
| CEPTAZ INJ 2GM/VIAL | 2 G | POWDER FOR SOLUTION | GLAXO CANADA INC | CANCELLED POST MARKET | 01974416 |
| CEPTAZ INJECTION - PWS IM IV 1G/VIAL | 1 G | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02215012 |
2 · Same class — other molecules in ATC J01DD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ceftriaxone | CEFTRIAXONE FOR INJECTION · CEFTRIAXONE FOR INJECTION USP · CEFTRIAXONE INJECTION, USP · CEFTRIAXONE SODIUM FOR INJECTION · +7 more | 41 | 13 | Yes |
| Ceftazidime | CEFTAZIDIME FOR INJECTION BP · CEFTAZIDIME FOR INJECTION, BP · CEFTAZIDIME FOR INJECTION, USP · CEPTAZ INJ 10GM/VIAL · +13 more | 23 | 6 | Yes |
| Cefixime | AURO-CEFIXIME · SUPRAX · SUPRAX - TAB 200MG | 8 | 4 | Yes |
| Cefotaxime | CEFOTAXIME SODIUM FOR INJECTION BP · CEFOTAXIME SODIUM FOR INJECTION, BP · CLAFORAN - PWS INJ 1.0G/VIAL · CLAFORAN - PWS INJ 2.0G/VIAL · +9 more | 21 | 2 | Yes |
| Ceftizoxime | CEFIZOX | 2 | 0 | Not in Canada |
| Cefpodoxime | ORELOX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEFTAZIDIME FOR INJECTION BP called?
The same molecule, Ceftazidime, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Fortum | Latin | Morocco, South Africa |
| Fetazim | Latin | Saudi Arabia |
| Zavicefta | Latin | Bahrain, South Africa |
| Ceftazidime Venus | Latin | Saudi Arabia |
| Loftaz | Latin | Saudi Arabia |
| NEGACEF | Latin | Bahrain |
| PYOCIADIM | Latin | Morocco |
| SEFOZID | Latin | Bahrain |
| Zidav | Latin | Saudi Arabia |
| ZIDIME | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.